We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

MALT1

MALT1 inhibitors target a paracaspase that relays antigen receptor signals in T and B lymphocytes. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) was first noted at chromosomal translocations in MALT lymphoma. After receptor stimulation it partners with B-cell lymphoma 10 (BCL10) to activate the nuclear factor kappa B (NF-κB) pathway. Its protease activity cleaves substrates after arginine residues and is required for full T cell activation. Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) depends on this activity, so inhibitors are studied in lymphoma and autoimmunity models. Listed compounds include MI 2, the peptide Z-VRPR-FMK, MLT-748, safimaltib and PROTAC MALT1 Degrader-1.

1 Item

  • PROTAC MALT1 Degrader-1
    Cat. No.
    A76594
    CAS No.
    2975664-37-8

    PROTAC MALT1 Degrader-1

    PROTAC MALT1 Degrader-1 is a selective degrader targeting MALT1 through the use of the PROTAC (proteolysis targeting chimera) technology. This compound facilitates the ubiquitination and subsequent proteasomal degradation of MALT1, making it a valuable tool for studies focused on lymphoma and related malignancies. Its mechanism of action enables the investigation of MALT1's role in cellular processes and therapeutic strategies for lymphoma treatment.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...